New registry to track MG drug safety in 1,500 patients
NCT ID NCT07217509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry will follow about 1,500 adults with myasthenia gravis (MG) to see how well current treatments work and how safe they are in real life. Doctors and patients will report data during routine visits. The goal is to better understand the disease and improve care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help doctors better understand how myasthenia gravis progresses and which treatments work best in everyday practice.
- What could go wrong
- This is an observational study, not a treatment trial. It collects data only, so it won't directly test or prove any new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CorEvitas, LLC
Waltham, Massachusetts, 02451, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking daily life unlock myasthenia gravis mysteries?
- Can engineered immune cells tame a debilitating autoimmune disease?
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can DNA reveal the roots of a rare muscle disease?
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Could a new drug help keep myasthenia gravis symptoms at bay?